{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:24:51Z","timestamp":1787498691118,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18K16377"],"award-info":[{"award-number":["18K16377"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K07139"],"award-info":[{"award-number":["21K07139"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2022,3,9]]},"DOI":"10.1038\/s41416-021-01639-9","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T12:13:41Z","timestamp":1638274421000},"page":"628-639","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Neoadjuvant therapy alters the collagen architecture of pancreatic cancer tissue via Ephrin-A5"],"prefix":"10.1038","volume":"126","author":[{"given":"Kosei","family":"Nakajima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Ino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chie","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3516-8765","authenticated-orcid":false,"given":"Satoshi","family":"Nara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Shimasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utako","family":"Ishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimitsu","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriteru","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Esaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoji","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4215-4385","authenticated-orcid":false,"given":"Nobuyoshi","family":"Hiraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,25]]},"reference":[{"key":"1639_CR1","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1056\/NEJMra0901557","volume":"362","author":"M Hidalgo","year":"2010","unstructured":"Hidalgo M. Pancreatic cancer. N. Engl J Med. 2010;362:1605\u201317.","journal-title":"N. Engl J Med"},{"key":"1639_CR2","unstructured":"Hruban RH, Adsay NV, Esposito I, Fukushima N, Furukawa T, Kloeppel G, et al. Pancreatic ductal adenocarcinoma. In: Board WCoTE (ed.) World Health Organization Classification of Tumours. 5th Edition. Digestive System Tumours, 5th edn. IARCPress: Lyon, 2019, pp. 322\u201332."},{"key":"1639_CR3","doi-asserted-by":"publisher","first-page":"v56","DOI":"10.1093\/annonc\/mdv295","volume":"26","author":"M Ducreux","year":"2015","unstructured":"Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goere D, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v56\u201368.","journal-title":"Ann Oncol"},{"key":"1639_CR4","first-page":"603","volume":"17","author":"MA Tempero","year":"2019","unstructured":"Tempero MA. NCCN Guidelines updates: pancreatic cancer. J Natl Compr Canc Netw. 2019;17:603\u20135.","journal-title":"J Natl Compr Canc Netw"},{"key":"1639_CR5","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.6004\/jnccn.2017.0131","volume":"15","author":"MA Tempero","year":"2017","unstructured":"Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, et al. Pancreatic adenocarcinoma, Version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15:1028\u201361.","journal-title":"J Natl Compr Canc Netw"},{"key":"1639_CR6","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.surg.2011.07.006","volume":"150","author":"MM Assifi","year":"2011","unstructured":"Assifi MM, Lu X, Eibl G, Reber HA, Li G, Hines OJ. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery. 2011;150:466\u201373.","journal-title":"Surgery"},{"key":"1639_CR7","doi-asserted-by":"publisher","first-page":"e1000267","DOI":"10.1371\/journal.pmed.1000267","volume":"7","author":"S Gillen","year":"2010","unstructured":"Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J. Preoperative\/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7:e1000267.","journal-title":"PLoS Med"},{"key":"1639_CR8","doi-asserted-by":"publisher","first-page":"LBA4002","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA4002","volume":"36","author":"GV Tienhoven","year":"2018","unstructured":"Tienhoven GV, Versteijne E, Suker M, Groothuis KBC, Busch OR, Bonsing BA, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): a randomized, controlled, multicenter phase III trial. J Clin Oncol. 2018;36:LBA4002.","journal-title":"J Clin Oncol"},{"key":"1639_CR9","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1245\/s10434-013-3390-y","volume":"21","author":"Y Homma","year":"2014","unstructured":"Homma Y, Taniguchi K, Murakami T, Nakagawa K, Nakazawa M, Matsuyama R, et al. Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2014;21:670\u20136.","journal-title":"Ann Surg Oncol"},{"key":"1639_CR10","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/jso.24681","volume":"116","author":"T Murakami","year":"2017","unstructured":"Murakami T, Homma Y, Matsuyama R, Mori R, Miyake K, Tanaka Y, et al. Neoadjuvant chemoradiotherapy of pancreatic cancer induces a favorable immunogenic tumor microenvironment associated with increased major histocompatibility complex class I-related chain A\/B expression. J Surg Oncol. 2017;116:416\u201326.","journal-title":"J Surg Oncol"},{"key":"1639_CR11","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1097\/MPA.0000000000000914","volume":"46","author":"R Nejati","year":"2017","unstructured":"Nejati R, Goldstein JB, Halperin DM, Wang H, Hejazi N, Rashid A, et al. Prognostic significance of tumor-infiltrating lymphocytes in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemotherapy. Pancreas. 2017;46:1180\u20137.","journal-title":"Pancreas"},{"key":"1639_CR12","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1158\/0008-5472.CAN-14-2921","volume":"75","author":"S Takeuchi","year":"2015","unstructured":"Takeuchi S, Baghdadi M, Tsuchikawa T, Wada H, Nakamura T, Abe H, et al. Chemotherapy-derived inflammatory responses accelerate the formation of immunosuppressive myeloid cells in the tissue microenvironment of human pancreatic cancer. Cancer Res. 2015;75:2629\u201340.","journal-title":"Cancer Res"},{"key":"1639_CR13","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/cas.12119","volume":"104","author":"T Tsuchikawa","year":"2013","unstructured":"Tsuchikawa T, Hirano S, Tanaka E, Matsumoto J, Kato K, Nakamura T, et al. Novel aspects of preoperative chemoradiation therapy improving anti-tumor immunity in pancreatic cancer. Cancer Sci. 2013;104:531\u20135.","journal-title":"Cancer Sci"},{"key":"1639_CR14","first-page":"337","volume":"38","author":"T Miyashita","year":"2018","unstructured":"Miyashita T, Tajima H, Makino I, Okazaki M, Yamaguchi T, Ohbatake Y, et al. Neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel reduces the number of cancer-associated fibroblasts through depletion of pancreatic stroma. Anticancer Res. 2018;38:337\u201343.","journal-title":"Anticancer Res"},{"key":"1639_CR15","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nrc.2016.73","volume":"16","author":"R Kalluri","year":"2016","unstructured":"Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16:582\u201398.","journal-title":"Nat Rev Cancer"},{"key":"1639_CR16","doi-asserted-by":"publisher","first-page":"e55146","DOI":"10.1371\/journal.pone.0055146","volume":"8","author":"Y Ino","year":"2013","unstructured":"Ino Y, Yamazaki-Itoh R, Oguro S, Shimada K, Kosuge T, Zavada J, et al. Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer. PLoS ONE. 2013;8:e55146.","journal-title":"PLoS ONE"},{"key":"1639_CR17","doi-asserted-by":"publisher","first-page":"7427","DOI":"10.1158\/1078-0432.CCR-03-0825","volume":"10","author":"T Armstrong","year":"2004","unstructured":"Armstrong T, Packham G, Murphy LB, Bateman AC, Conti JA, Fine DR, et al. Type I collagen promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2004;10:7427\u201337.","journal-title":"Clin Cancer Res"},{"key":"1639_CR18","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.canlet.2014.10.020","volume":"356","author":"S Berchtold","year":"2015","unstructured":"Berchtold S, Grunwald B, Kruger A, Reithmeier A, Hahl T, Cheng T, et al. Collagen type V promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Cancer Lett. 2015;356:721\u201332.","journal-title":"Cancer Lett"},{"key":"1639_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-154","volume":"13","author":"D Ohlund","year":"2013","unstructured":"Ohlund D, Franklin O, Lundberg E, Lundin C, Sund M. Type IV collagen stimulates pancreatic cancer cell proliferation, migration, and inhibits apoptosis through an autocrine loop. BMC Cancer. 2013;13:154.","journal-title":"BMC Cancer"},{"key":"1639_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms16031","volume":"8","author":"O Olivares","year":"2017","unstructured":"Olivares O, Mayers JR, Gouirand V, Torrence ME, Gicquel T, Borge L, et al. Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions. Nat Commun. 2017;8:16031.","journal-title":"Nat Commun"},{"key":"1639_CR21","doi-asserted-by":"publisher","first-page":"10495","DOI":"10.1074\/jbc.M110.195628","volume":"286","author":"MA Shields","year":"2011","unstructured":"Shields MA, Dangi-Garimella S, Krantz SB, Bentrem DJ, Munshi HG. Pancreatic cancer cells respond to type I collagen by inducing snail expression to promote membrane type 1 matrix metalloproteinase-dependent collagen invasion. J Biol Chem. 2011;286:10495\u2013504.","journal-title":"J Biol Chem"},{"key":"1639_CR22","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.bbrc.2006.09.085","volume":"350","author":"TN Campbell","year":"2006","unstructured":"Campbell TN, Attwell S, Arcellana-Panlilio M, Robbins SM. Ephrin A5 expression promotes invasion and transformation of murine fibroblasts. Biochem Biophys Res Commun. 2006;350:623\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"1639_CR23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"1639_CR24","doi-asserted-by":"crossref","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours, 8th ed. Wiley-Blackwell: Hoboken, NJ, 2017.","DOI":"10.1002\/9780471420194.tnmc26.pub3"},{"key":"1639_CR25","unstructured":"Japan-Pancreas-Society. Classification of Pancreatic Cancer, 3rd English ed. Kanehara: Tokyo, Japan, 2011."},{"key":"1639_CR26","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1111\/cas.14514","volume":"111","author":"N Hiraoka","year":"2020","unstructured":"Hiraoka N, Ino Y, Hori S, Yamazaki-Itoh R, Naito C, Shimasaki M, et al. Expression of classical human leukocyte antigen class I antigens, HLA-E and HLA-G, is adversely prognostic in pancreatic cancer patients. Cancer Sci. 2020;111:3057\u201370.","journal-title":"Cancer Sci"},{"key":"1639_CR27","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1111\/cas.12825","volume":"106","author":"S Oguro","year":"2015","unstructured":"Oguro S, Ino Y, Shimada K, Hatanaka Y, Matsuno Y, Esaki M, et al. Clinical significance of tumor-infiltrating immune cells focusing on BTLA and Cbl-b in patients with gallbladder cancer. Cancer Sci. 2015;106:1750\u201360.","journal-title":"Cancer Sci"},{"key":"1639_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8866","volume":"6","author":"JA Ramilowski","year":"2015","unstructured":"Ramilowski JA, Goldberg T, Harshbarger J, Kloppmann E, Lizio M, Satagopam VP, et al. A draft network of ligand-receptor-mediated multicellular signaling in human. Nat Commun. 2015;6:7866.","journal-title":"Nat Commun"},{"key":"1639_CR29","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.18632\/oncotarget.26646","volume":"10","author":"Y Ino","year":"2019","unstructured":"Ino Y, Oguro S, Yamazaki-Itoh R, Hori S, Shimada K, Hiraoka N. Reliable evaluation of tumor-infiltrating lymphocytes in pancreatic cancer tissue biopsies. Oncotarget. 2019;10:1149\u201359.","journal-title":"Oncotarget"},{"key":"1639_CR30","doi-asserted-by":"publisher","first-page":"e0242851","DOI":"10.1371\/journal.pone.0242851","volume":"15","author":"N Doi","year":"2020","unstructured":"Doi N, Ino Y, Angata K, Shimada K, Narimatsu H, Hiraoka N. Clinicopathological significance of core 3 O-glycan synthetic enzyme, beta1,3-N-acetylglucosaminyltransferase 6 in pancreatic ductal adenocarcinoma. PLoS ONE. 2020;15:e0242851.","journal-title":"PLoS ONE"},{"key":"1639_CR31","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/00006676-199511000-00007","volume":"11","author":"T Imamura","year":"1995","unstructured":"Imamura T, Iguchi H, Manabe T, Ohshio G, Yoshimura T, Wang ZH, et al. Quantitative analysis of collagen and collagen subtypes I, III, and V in human pancreatic cancer, tumor-associated chronic pancreatitis, and alcoholic chronic pancreatitis. Pancreas. 1995;11:357\u201364.","journal-title":"Pancreas"},{"key":"1639_CR32","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1242\/dev.038935","volume":"136","author":"D Julich","year":"2009","unstructured":"Julich D, Mould AP, Koper E, Holley SA. Control of extracellular matrix assembly along tissue boundaries via Integrin and Eph\/Ephrin signaling. Development. 2009;136:2913\u201321.","journal-title":"Development"},{"key":"1639_CR33","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1038\/nm.4419","volume":"23","author":"D Lagares","year":"2017","unstructured":"Lagares D, Ghassemi-Kakroodi P, Tremblay C, Santos A, Probst CK, Franklin A, et al. ADAM10-mediated ephrin-B2 shedding promotes myofibroblast activation and organ fibrosis. Nat Med. 2017;23:1405\u201315.","journal-title":"Nat Med"},{"key":"1639_CR34","doi-asserted-by":"publisher","first-page":"9419","DOI":"10.1074\/jbc.M110.197087","volume":"286","author":"R Walsh","year":"2011","unstructured":"Walsh R, Blumenberg M. Specific and shared targets of ephrin A signaling in epidermal keratinocytes. J Biol Chem. 2011;286:9419\u201328.","journal-title":"J Biol Chem"},{"key":"1639_CR35","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1038\/sj.bjc.6604676","volume":"99","author":"Q Chang","year":"2008","unstructured":"Chang Q, Jorgensen C, Pawson T, Hedley DW. Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer. Br J Cancer. 2008;99:1074\u201382.","journal-title":"Br J Cancer"},{"key":"1639_CR36","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/sj.onc.1207247","volume":"23","author":"MS Duxbury","year":"2004","unstructured":"Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene. 2004;23:1448\u201356.","journal-title":"Oncogene"},{"key":"1639_CR37","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/nrc2806","volume":"10","author":"EB Pasquale","year":"2010","unstructured":"Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer. 2010;10:165\u201380.","journal-title":"Nat Rev Cancer"},{"key":"1639_CR38","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nn1237","volume":"7","author":"JP Himanen","year":"2004","unstructured":"Himanen JP, Chumley MJ, Lackmann M, Li C, Barton WA, Jeffrey PD, et al. Repelling class discrimination: ephrin-A5 binds to and activates EphB2 receptor signaling. Nat Neurosci. 2004;7:501\u20139.","journal-title":"Nat Neurosci"},{"key":"1639_CR39","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/S0955-0674(97)80113-5","volume":"9","author":"EB Pasquale","year":"1997","unstructured":"Pasquale EB. The Eph family of receptors. Curr Opin Cell Biol. 1997;9:608\u201315.","journal-title":"Curr Opin Cell Biol"},{"key":"1639_CR40","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s12253-009-9221-6","volume":"16","author":"C Giaginis","year":"2010","unstructured":"Giaginis C, Tsourouflis G, Zizi-Serbetzoglou A, Kouraklis G, Chatzopoulou E, Dimakopoulou K, et al. Clinical significance of ephrin (eph)-A1, -A2, -a4, -a5 and -a7 receptors in pancreatic ductal adenocarcinoma. Pathol Oncol Res. 2010;16:267\u201376.","journal-title":"Pathol Oncol Res"},{"key":"1639_CR41","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10585-006-9045-7","volume":"23","author":"SV Mudali","year":"2006","unstructured":"Mudali SV, Fu B, Lakkur SS, Luo M, Embuscado EE, Iacobuzio-Donahue CA. Patterns of EphA2 protein expression in primary and metastatic pancreatic carcinoma and correlation with genetic status. Clin Exp Metastasis. 2006;23:357\u201365.","journal-title":"Clin Exp Metastasis"},{"key":"1639_CR42","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1172\/JCI127755","volume":"129","author":"N Markosyan","year":"2019","unstructured":"Markosyan N, Li J, Sun YH, Richman LP, Lin JH, Yan F, et al. Tumor cell-intrinsic EPHA2 suppresses anti-tumor immunity by regulating PTGS2 (COX-2). J Clin Invest. 2019;129:3594\u2013609.","journal-title":"J Clin Invest"},{"key":"1639_CR43","first-page":"79","volume":"75","author":"CS Lee","year":"1994","unstructured":"Lee CS, Montebello J, Georgiou T, Rode J. Distribution of type IV collagen in pancreatic adenocarcinoma and chronic pancreatitis. Int J Exp Pathol. 1994;75:79\u201383.","journal-title":"Int J Exp Pathol"},{"key":"1639_CR44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc2748","volume":"10","author":"JS Desgrosellier","year":"2010","unstructured":"Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10:9\u201322.","journal-title":"Nat Rev Cancer"},{"key":"1639_CR45","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/sj.bjc.6603088","volume":"94","author":"JJ Grzesiak","year":"2006","unstructured":"Grzesiak JJ, Bouvet M. The alpha2beta1 integrin mediates the malignant phenotype on type I collagen in pancreatic cancer cell lines. Br J Cancer. 2006;94:1311\u20139.","journal-title":"Br J Cancer"},{"key":"1639_CR46","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1158\/0008-5472.CAN-17-2320","volume":"78","author":"P Dauer","year":"2018","unstructured":"Dauer P, Zhao X, Gupta VK, Sharma N, Kesh K, Gnamlin P, et al. Inactivation of cancer-associated-fibroblasts disrupts oncogenic signaling in pancreatic cancer cells and promotes its regression. Cancer Res. 2018;78:1321\u201333.","journal-title":"Cancer Res"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01639-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01639-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01639-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T04:11:54Z","timestamp":1720757514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01639-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,25]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,3,9]]}},"alternative-id":["1639"],"URL":"https:\/\/doi.org\/10.1038\/s41416-021-01639-9","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,25]]},"assertion":[{"value":"28 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Board of the National Cancer Center, Japan (#2005-077 and #2016-006). Informed consent was obtained from all participants involved in the study, and all clinical investigations were conducted in line with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"There are no individual person\u2019s data from all participants involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}